All In Biotech

Drug Trial Radar · NCT06101095

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE)

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

69

Actual

Start

Nov 29, 2023

Primary completion

Nov 5, 2025

Study completion Feb 1, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Oct 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) * Screening period: Up to 12 weeks before Week 0 * Randomized double-blind period: 24 weeks * Open label period: 104 weeks * Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first. There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).

Conditions

  • Eosinophilic Oesophagitis

Interventions

  • DupilumabDrug

    Subcutaneous injection (SC) as per protocol

  • PlaceboDrug

    SC injection as per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)Time frame: From baseline to Week 24

Locations

30 sites in 5 countries. Site status is shown where the registry gives one.

  • United Gastroenterologists - Murrieta- Site Number : 8400001

    Murrieta, California

  • University of California San Francisco - Parnassus Heights- Site Number : 8400020

    San Francisco, California

  • Borland Groover Clinic- Site Number : 8400016

    Jacksonville, Florida

  • Treasure Valley Medical Research- Site Number : 8400018

    Boise, Idaho

  • Northwestern University- Site Number : 8400003

    Chicago, Illinois

  • GI Alliance - Glenview- Site Number : 8400012

    Glenview, Illinois

  • Illinois Gastroenterology Group- Site Number : 8400004

    Gurnee, Illinois

  • University of Iowa- Site Number : 8400006

    Iowa City, Iowa

  • University of Massachusetts Chan Medical School- Site Number : 8400019

    Worcester, Massachusetts

  • Mayo Clinic Hospital Rochester- Site Number : 8400008

    Rochester, Minnesota

  • University of North Carolina at Chapel Hill- Site Number : 8400007

    Chapel Hill, North Carolina

  • Cleveland Clinic - Cleveland- Site Number : 8400009

    Cleveland, Ohio

  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010

    Philadelphia, Pennsylvania

  • Private Practice - Dr. Martin Yudovich- Site Number : 8400015

    Houston, Texas

  • GI Alliance - Mansfield- Site Number : 8400017

    Mansfield, Texas

  • Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003

    São Paulo, Brazil

  • Itaigara Memorial - Hospital Dia- Site Number : 0760005

    Salvador, Estado de Bahia, Brazil

  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clínica Loema - Unidade I- Site Number : 0760007

    Campinas, São Paulo, Brazil

  • Clinica de Alergia Martti Antila- Site Number : 0760001

    Sorocaba, São Paulo, Brazil

  • Investigational Site Number : 1240006

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240004

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240002

    Montreal, Quebec, Canada

  • Investigational Site Number : 3760006

    Haifa, Israel

  • Investigational Site Number : 3760002

    Haifa, Israel

  • Investigational Site Number : 3760005

    Jerusalem, Israel

  • Investigational Site Number : 3760004

    Jerusalem, Israel

  • Investigational Site Number : 3760003

    Tel Aviv, Israel

  • Investigational Site Number : 7560001

    Wetzikon, Switzerland

  • Investigational Site Number : 7560002

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.